Tonix Pharmaceuticals
TNXP
14 hedge funds and large institutions have $2.01M invested in Tonix Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
25% more capital invested
Capital invested by funds: $1.62M → $2.01M (+$397K)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.66M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.43M |
| 3 |
VF
Virtu Financial
New York
|
+$76.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.9K |
| 5 |
Millennium Management
New York
|
+$21.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$70.1K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$58.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$39.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$29.2K |
| 5 |
Two Sigma Investments
New York
|
-$20.1K |
TNXP Hedge Fund Activity: Q3 2023 in Review
14 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2023, worth a combined $2.01M — up 25% from $1.62M a quarter earlier.
Fund positioning in TNXP was balanced in Q3 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.66M. The largest seller was Raymond James & Associates, exiting entirely with an estimated $70.1K sold.
- 14 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $2.01M of Tonix Pharmaceuticals stock for Q3 2023, up 25% quarter-over-quarter.
- 4 funds opened new Tonix Pharmaceuticals positions in Q3 2023 and 4 closed out, a net change of 0 holders.
- The largest Tonix Pharmaceuticals buyer in Q3 2023 was Armistice Capital, an estimated $1.66M added.
- The largest Tonix Pharmaceuticals seller in Q3 2023 was Raymond James & Associates, an estimated $70.1K sold.
Based on aggregated 13F filings for Q3 2023.